idiopath
pulmonari
fibrosi
ipf
chronic
slowli
progress
diseas
abrupt
worsen
without
identifi
caus
known
acut
exacerb
ae
ipf
uncommon
recent
signific
aeipf
becom
evid
aeipf
major
caus
morbid
mortal
patient
ipf
account
half
hospit
admiss
kubo
et
al
song
et
al
teramachi
et
al
death
natsuizaka
et
al
autopsi
find
also
shown
ae
common
immedi
caus
death
patient
ipf
daniel
et
al
ae
usual
occur
later
cours
diseas
song
et
al
collard
et
al
collard
et
al
ohshimo
et
al
schupp
et
al
patient
experienc
ae
may
establish
diagnosi
ipf
thu
ae
first
manifest
underli
preexist
ipf
kim
et
al
although
real
natur
ae
includ
incid
etiolog
pathogenesi
still
clear
proven
effect
therapi
much
progress
made
sinc
consensu
statement
publish
propos
clear
definit
diagnost
criteria
first
time
revis
definit
broaden
inclus
criteria
make
diagnosi
aeipf
feasibl
clinic
practic
help
research
clarifi
natur
aeipf
find
effect
treatment
articl
review
summar
present
understand
aeipf
nation
institut
healthsponsor
ipf
clinic
network
clinic
expert
propos
consensu
definit
diagnost
criteria
aeipf
collard
et
al
criteria
includ
clinic
worsen
less
day
durat
presenc
new
radiolog
abnorm
highresolut
comput
tomographi
hrct
bilater
groundglass
opacificationconsolid
exclus
altern
etiolog
endobronchi
aspir
bronchoalveolar
lavag
bal
recommend
exclud
potenti
infecti
etiolog
suspect
aeipf
propos
case
miss
data
collard
et
al
consensu
criteria
origin
propos
standard
inclus
criteria
futur
research
howev
perform
bronchoscopi
often
clinic
feasibl
patient
signific
hypoxemia
even
perform
frequent
confid
exclud
underli
infect
furthermor
evid
demonstr
aeipf
similar
clinic
featur
prognosi
compar
nonidiopath
caus
acut
respiratori
worsen
ipf
eg
infect
aspir
collard
et
al
therefor
intern
work
group
publish
revis
definit
aeipf
collard
et
al
current
guidelin
aeipf
defin
clinic
signific
respiratori
deterior
develop
within
typic
less
month
accompani
new
radiolog
abnorm
hrct
diffus
bilater
groundglass
opacif
without
consolid
absenc
obviou
clinic
caus
like
fluid
overload
left
heart
failur
pulmonari
embol
revis
definit
term
idiopath
omit
allow
broader
inclus
exacerb
includ
may
trigger
thu
enabl
futur
research
better
understand
aeipf
find
effect
therapi
condit
clinic
scenario
exclud
fluid
overload
left
heart
failur
pulmonari
embol
mention
condit
differ
prognosi
requir
differ
therapi
compar
aeipf
new
definit
promot
discrimin
trigger
form
aeipf
eg
infect
postproceduralpostop
drug
toxic
idiopath
form
aeipf
trigger
identifi
tabl
report
incid
ae
highli
variabl
less
almost
half
patient
ipf
due
differ
criteria
differ
patient
popul
studi
shown
tabl
incid
ae
placebo
arm
random
control
trial
rct
low
contrast
incid
retrospect
cohort
studi
collard
et
al
earlier
rct
ae
predefin
list
secondari
end
point
therefor
incid
mention
occasion
patient
idiopath
clinic
worsen
fail
meet
five
criteria
due
miss
data
term
suspect
acut
exacerb
diagnosi
idiopath
pulmonari
fibrosi
previous
establish
criterion
met
presenc
radiolog
andor
histopatholog
chang
consist
usual
interstiti
pneumonia
pattern
current
evalu
b
previou
highresolut
comput
tomographi
avail
qualifi
new
drop
new
diffus
pulmonari
infiltr
visual
chest
radiographi
hrct
develop
parenchym
abnorm
pneumothorax
pleural
effus
new
groundglass
opac
sinc
preced
visit
exclus
known
caus
acut
worsen
includ
infect
left
heart
failur
pulmonari
embol
identifi
caus
acut
lung
injuri
accord
routin
clinic
practic
microbiolog
studi
ae
specifi
data
mention
acut
decompens
acut
decompens
unexplain
rapid
deterior
week
increas
dyspnea
requir
hospit
oxygen
supplement
lmin
maintain
rest
oxygen
satur
arteri
blood
ga
sao
pao
mmhg
sea
level
mmhg
capac
worsen
pao
mmhg
drop
recent
preworsen
clinic
signific
worsen
dyspnea
continu
acut
decompens
acut
worsen
acut
respiratori
failur
rct
perform
mild
moder
sever
ipf
without
signific
comorbid
contrast
poor
lung
function
consist
risk
factor
ae
cohort
studi
therefor
incid
ae
rct
may
lower
incid
gener
patient
popul
due
exclus
ipf
patient
sever
diseas
definit
ae
import
post
hoc
analysi
sildenafil
trial
exercis
perform
idiopath
pulmonari
fibrosi
stepipf
zisman
et
al
definit
aeipf
occur
per
patientyear
combin
definit
suspect
aeipf
increas
incid
per
patientyear
collard
et
al
annual
rate
ae
registrybas
us
studi
even
lower
per
patientyear
fernandez
perez
et
al
poor
lung
function
advanc
diseas
advanc
diseas
low
lung
function
consist
risk
factor
aeipf
major
studi
includ
low
forc
vital
capac
fvc
song
et
al
collard
et
al
collard
et
al
ohshimo
et
al
schupp
et
al
low
diffus
capac
carbon
monoxid
dlco
miyazaki
et
al
collard
et
al
schupp
et
al
low
total
lung
capac
tlc
miyazaki
et
al
qiu
et
al
lower
walk
distanc
collard
et
al
impair
baselin
oxygen
collard
et
al
collard
et
al
kondoh
et
al
recent
declin
fvc
reichmann
et
al
increas
dyspnea
collard
et
al
suggest
advanc
diseas
may
increas
real
incid
increas
chanc
recognit
due
symptom
sign
patient
alreadi
poor
physiolog
reserv
howev
higher
occurr
ae
patient
lower
lung
function
seen
cohort
studi
also
observ
rct
inpulsi
trial
aeipf
secondari
end
point
ae
patient
fvc
predict
fvc
predict
incid
costabel
et
al
also
metaanalysi
six
rct
show
ae
occur
less
frequent
trial
exclud
sever
diseas
vs
patient
year
p
atkin
et
al
inpulsison
studi
openlabel
extens
inpulsi
trial
post
hoc
subgroup
analysi
demonstr
progress
diseas
fatal
event
frequent
subgroup
patient
sever
diseas
fvc
start
extens
phase
patient
less
sever
diseas
although
differ
statist
signific
wuyt
et
al
acut
exacerb
report
common
patient
previou
histori
ae
kubo
et
al
johannson
et
al
reichmann
et
al
sato
et
al
coexist
pulmonari
hypertens
judg
et
al
qiu
et
al
coronari
arteri
diseas
collard
et
al
report
risk
factor
aeipf
higher
serum
kreb
von
level
elev
serum
level
baselin
associ
increas
risk
aeipf
adjust
clinic
featur
includ
vital
capac
vc
ohshimo
et
al
sato
et
al
report
multivari
analysi
along
surgic
procedur
histori
ae
vc
male
sex
independ
risk
factor
occurr
ae
case
lung
cancer
ipf
sato
et
al
qui
et
al
report
higher
serum
poor
pulmonari
function
mechan
procedur
new
superimpos
ggo
hrct
lobe
caus
cardiac
thromboembol
aspir
infecti
process
rule
stepipf
acut
exacerb
follow
three
criteria
defin
ae
subject
acut
worsen
respiratori
condit
clinic
follow
requir
unexplain
worsen
dyspnea
cough
within
day
trigger
unschedul
medic
care
eg
clinic
studi
visit
hospit
b
clinic
suspicion
overt
evid
cardiac
event
pulmonari
embol
deep
venou
thrombosi
explain
acut
worsen
dyspnea
c
pneumothorax
radiologicphysiolog
follow
requir
new
groundglass
opac
consolid
comput
tomographi
ct
scan
new
alveolar
opac
chest
xray
b
declin
rest
room
air
spo
last
record
level
declin
mmhg
rest
room
air
pao
last
record
level
microbiolog
follow
requir
clinic
evid
infect
ie
absenc
grossli
purul
sputum
fever
c
oral
b
microbiolog
evid
infect
ie
clinic
signific
bacteri
growth
sputum
endotrach
aspir
cultur
quantit
cultur
protect
brush
specimen
cfuml
bronchoalveolar
lavag
cfuml
presenc
specif
pathogen
stain
secondari
pulmonari
hypertens
associ
increas
risk
aeipf
metaanalysi
seven
studi
qiu
et
al
kondoh
et
al
report
high
bmi
risk
factor
ae
conflict
data
qiu
et
al
controversi
effect
smoke
ae
ipf
song
et
al
kishaba
et
al
report
increas
incid
ae
neversmok
ipf
patient
neversmok
vs
eversmok
p
howev
studi
observ
higher
risk
former
smoker
ohshimo
et
al
collard
et
al
suggest
east
asian
patient
popul
may
greater
risk
ae
compar
patient
race
howev
inpulsi
studi
incid
ae
asian
patient
similar
white
placebo
nintedanib
group
among
asian
ae
develop
nintedanib
group
placebo
group
caucasian
patient
ae
report
nintedanib
group
placebo
group
taniguchi
et
al
case
aeipf
caus
trigger
factor
certain
case
ae
develop
preced
event
follow
surgeri
administr
pulmonarytox
medic
follow
trigger
factor
report
aeipf
fever
flulik
symptom
neutrophilia
bal
fluid
specimen
implic
underli
infecti
etiolog
especi
viral
mani
studi
report
ae
occur
frequent
winter
spring
month
simonblanc
et
al
costabel
et
al
oda
et
al
patient
take
immunosuppress
medic
one
larg
studi
patient
ild
case
ipf
case
nonipf
show
patient
diagnos
infect
set
acut
respiratori
worsen
moua
et
al
although
accompani
clinic
featur
suggest
infecti
etiolog
effort
prove
infect
aeipf
success
wootton
et
al
test
bal
fluid
serum
patient
aeipf
stabl
ipf
acut
lung
injuri
ali
without
ipf
viral
nucleic
acid
use
multiplex
polymeras
chain
reaction
test
panvir
microarray
highthroughput
cdna
sequenc
patient
aeipf
four
evid
common
respiratori
viru
parainfluenza
rhinoviru
n
coronaviru
virus
detect
stabl
ipf
patient
addit
panvir
microarray
reveal
evid
nonrespiratori
virus
patient
aeipf
herp
simplex
viru
epsteinbarr
viru
torqu
teno
viru
ttv
ttv
found
similar
percentag
patient
ali
clinic
signific
ttv
remain
determin
konishi
et
al
also
fail
identifi
gene
transcript
profil
would
expect
viral
infect
patient
aeipf
stabl
ipf
konishi
et
al
prospect
studi
c
pneumonia
infect
trigger
aeipf
two
patient
antibodi
respons
tomioka
et
al
suggest
chlamydophila
unlik
trigger
aeipf
although
exist
data
support
role
infectionvirus
even
major
case
ae
still
possibl
infect
trigger
ae
due
rel
insidi
onset
ae
day
trigger
virus
would
like
longer
detect
time
clinic
present
ae
leav
acut
lung
injuri
pattern
aggrav
acceler
underli
interstiti
lung
diseas
ild
also
detect
infect
difficult
even
invas
procedur
autopsi
studi
found
patient
aeipf
bronchopneumonia
fungal
cytomegaloviru
bacteri
identifi
postmortem
clinic
unsuspect
highlight
difficulti
diagnos
infect
set
oda
et
al
recent
studi
bronchoscopi
perform
ild
patient
present
acut
respiratori
failur
show
reveal
potenti
caus
respiratori
worsen
arcadu
moua
furthermor
identifi
infect
yet
demonstr
affect
outcom
despit
treatment
microorgan
identifi
bal
fluid
fatal
outcom
eventu
occur
mortal
remain
high
blivet
et
al
recent
studi
human
lung
microbiom
shown
chang
number
composit
may
play
import
role
pathogenesi
progress
lung
diseas
includ
ipf
han
et
al
molyneaux
et
al
integr
analysi
host
transcriptom
microbi
signatur
demonstr
interact
host
environ
ipf
respons
alter
abund
microbiom
remain
longitudin
followup
suggest
bacteri
commun
lower
airway
may
act
persist
stimulu
repetit
alveolar
injuri
ipf
molyneaux
et
al
bal
fluid
aeipf
bacteri
burden
also
increas
compar
stabl
ipf
increas
campylobact
sp
stenotrophomona
sp
well
signific
decreas
veillonella
sp
compar
stabl
ipf
molyneaux
et
al
find
suggest
infect
may
import
trigger
aeipf
even
though
presenc
microbi
organ
detect
although
increas
number
studi
document
high
preval
gerd
patient
ipf
raghu
meyer
lee
et
al
direct
evid
causal
relationship
increas
pepsin
level
bal
fluid
patient
aeipf
lee
et
al
stovold
et
al
suggest
ger
aspir
gastric
acid
nonacid
compon
may
trigger
episod
ae
anim
studi
demonstr
instil
acid
gastric
juic
provok
diffus
alveolar
damag
pattern
patholog
pattern
aeipf
lee
et
al
report
placebo
arm
three
rct
stepipf
aceipf
pantheripf
patient
take
antiacid
therapi
baselin
slower
declin
fvc
l
vs
l
p
fewer
ae
event
versu
nine
event
p
studi
period
lee
et
al
recent
studi
report
proton
pump
inhibitor
ppi
possess
antiinflammatori
antifibrot
activ
directli
suppress
proinflammatori
cytokin
profibrot
protein
prolifer
lung
fibroblast
ghebr
raghu
howev
associ
controversi
small
cohort
studi
h
pylori
lung
tissu
report
relev
differ
ae
event
gastroesophag
reflux
diseas
gerd
nongerd
ipf
subgroup
kreuter
et
al
also
recent
pool
inpulsi
data
show
frequenc
investigatorreport
ae
higher
among
patient
antacid
medic
baselin
placebo
group
compar
antacid
placebo
group
differ
ae
rate
antacid
nintedanib
group
vs
respect
costabel
et
al
studi
asymmetr
ipf
rate
ger
higher
patient
asymmetr
ipf
match
symmetr
ipf
p
similarli
ae
significantli
frequent
asymmetr
ipf
vs
p
patient
develop
ae
ground
glass
opac
ggo
virtual
unilater
occur
affect
lung
ipf
case
right
side
suggest
locoregion
factor
includ
ger
may
respons
asymmetri
occurr
ae
tcherakian
et
al
howev
later
callahan
report
statist
signific
differ
number
ae
vs
p
ger
group
observ
asymmetr
case
ipf
compar
control
callahan
et
al
data
interpret
caution
number
subject
smaller
incid
ae
symmetr
ipf
group
seem
rel
high
compar
report
three
patient
asymmetr
group
strictli
unilater
involv
patient
left
lung
domin
diseas
last
wrapipf
raghu
et
al
phase
prospect
unblind
rct
laparoscop
antireflux
surgeri
patient
ipf
abnorm
acid
ger
show
ae
vs
p
respiratoryrel
hospit
vs
p
death
vs
p
less
common
surgeri
group
meet
statist
signific
consid
potenti
side
effect
associ
long
term
ppi
use
freedberg
et
al
increas
risk
infect
includ
pulmonari
infect
observ
mani
report
kreuter
et
al
costabel
et
al
welldesign
prospect
rct
requir
understand
relationship
ger
ipf
also
evalu
safeti
therapeut
efficaci
ppi
antacid
antireflux
surgeri
ipf
recent
singlecent
doubl
blind
rct
omeprazol
ipf
dutta
et
al
suggest
feasibl
larger
rct
although
question
gold
standard
method
diagnosi
ger
especi
larg
clinic
rct
remain
aeipf
develop
pulmonari
resect
due
lung
cancer
report
occur
watanab
et
al
sakamoto
et
al
suzuki
et
al
song
et
al
mizuno
et
al
ae
report
occur
nonpulmonari
surgeri
ghatol
et
al
choi
et
al
surgic
lung
biopsi
although
incid
rate
low
kondoh
et
al
park
et
al
bando
et
al
samejima
et
al
case
aeipf
also
report
follow
bal
hiwatari
et
al
kim
et
al
sakamoto
et
al
cryobiopsi
casoni
et
al
tomic
et
al
dhooria
et
al
mechan
ae
set
certain
may
due
increas
suscept
addit
mechan
stress
alreadi
fibrot
noncompli
ipf
lung
aeipf
also
observ
patient
receiv
chemotherapi
lung
cancer
follow
radiotherapi
goto
et
al
watanab
et
al
minegishi
et
al
report
ae
develop
chemotherapi
singl
drug
multipl
drug
radiat
therapi
also
occur
patient
receiv
support
care
without
therapi
minegishi
et
al
exposur
increas
ozon
nitrogen
dioxid
level
ambient
air
report
associ
aeipf
johannson
et
al
patholog
find
aeipf
compris
underli
usual
interstiti
pneumonia
uip
three
type
acut
lung
injuri
pattern
diffus
alveolar
damag
dad
organ
pneumonia
op
without
evid
organ
dad
extens
fibroblast
foci
churg
et
al
patient
op
pattern
extens
fibroblast
foci
appear
better
prognosi
churg
et
al
akira
et
al
report
patient
op
extens
fibroblast
foci
peripher
type
ggo
hrct
find
surgic
lung
biopsi
differ
autopsi
specimen
oda
et
al
autopsi
specimen
uip
seen
dad
pulmonari
hemorrhag
thromboembol
lung
cancer
addit
show
bronchopneumonia
op
without
dad
found
might
relat
better
prognosi
op
pattern
consequ
seen
less
frequent
autopsi
recent
balestero
et
al
perform
morphometr
analysi
explant
lung
specimen
patient
ipf
includ
aeipf
compar
patholog
find
clinic
diseas
progress
promin
cellular
inflammatori
infiltr
number
innat
neutrophil
macrophag
adapt
inflammatori
infiltr
cd
b
cell
significantli
higher
acut
exacerb
rapid
progressor
compar
slow
progressor
slow
progressor
develop
ae
show
mark
increas
overal
inflamm
slow
progressor
develop
ae
inde
degre
inflamm
rapid
progressor
exacerb
similar
acut
exacerb
interestingli
dad
consid
characterist
featur
ae
also
found
extent
rapid
progressor
exacerb
balestro
et
al
mani
blood
biomark
report
role
predict
clinic
cours
outcom
aeild
includ
lactat
dehydrogenas
ldh
creactiv
protein
crp
surfact
proteind
spd
miyazaki
et
al
kishaba
et
al
simonblanc
et
al
song
et
al
procalcitonin
ding
et
al
circul
fibrocyt
moeller
et
al
tachibana
et
al
antiheat
shock
protein
autoantibodi
kakugawa
et
al
kahloon
et
al
alphadefensin
decorin
nikaido
et
al
syndecan
sato
et
al
howev
none
properli
valid
prospect
studi
biomark
current
impact
clinic
decis
make
ae
kondoh
et
al
mucinlik
glycoprotein
mainli
express
type
ii
pneumocyt
bronchial
epitheli
cell
kohno
et
al
detect
regener
type
ii
cell
kohno
et
al
wide
use
japan
serum
marker
predict
diseas
cours
develop
aeipf
ohshimo
et
al
recent
maher
et
al
found
spd
discriminatori
biomark
patient
ipf
valid
patient
enrol
prospect
multicent
observ
cohort
studi
incid
case
fibrot
interstiti
lung
diseas
profil
studi
baselin
valu
spd
ng
ml
vs
ng
ml
p
uml
vs
uml
p
significantli
higher
patient
progress
diseas
patient
stabl
diseas
rise
concentr
month
associ
increas
risk
mortal
hr
ci
p
associ
ae
unknown
maher
et
al
proven
effect
treatment
aeipf
clinic
practic
highdos
corticosteroid
wide
use
current
intern
guidelin
weak
recommend
use
sole
base
high
mortal
aeipf
anecdot
report
benefit
howev
control
trial
data
support
efficaci
safeti
corticosteroid
aeipf
studi
report
better
surviv
combin
immunosuppress
agent
like
cyclophosphamid
ctx
cyclosporinea
csa
tacrolimu
autoantibodi
reduct
therapi
rituximab
combin
therapeut
plasma
exchang
intraven
immunoglobulin
donaho
et
al
innov
procedur
polymyxin
bimmobil
fiber
column
direct
hemoperfus
pmxdhp
recombin
human
thrombomodulin
rh
tm
tri
mostli
japan
howev
studi
often
small
retrospect
observ
cohort
studi
control
studi
compar
histor
andor
parallel
untreat
control
obviou
hidden
confound
factor
like
select
bia
differ
gener
support
care
result
therapeut
trial
aeipf
summar
tabl
tabl
summari
treatment
studi
acut
exacerb
idiopath
pulmonari
fibrosi
studi
subject
includ
patient
treat
nacetylcystein
although
corticosteroid
administ
patient
aeipf
actual
report
data
limit
placebo
control
studi
corticosteroid
use
control
studi
corticosteroid
group
use
control
group
report
outcom
shown
tabl
inas
et
al
sakamoto
et
al
horita
et
al
tsushima
et
al
studi
small
retrospect
singl
center
report
surviv
rate
highli
variabl
rate
rang
result
acut
exacerb
develop
lung
resect
nine
patient
cancer
mainli
around
largest
studi
song
et
al
report
inhospit
surviv
rate
patient
treat
variabl
dose
corticosteroid
monotherapi
median
surviv
report
two
studi
day
day
horita
et
al
sakamoto
et
al
data
cyclophosphamid
ctx
monotherapi
studi
ctx
given
corticosteroid
ambrosini
et
al
report
monthsurviv
rate
five
studi
subject
ambrosini
et
al
studi
morawiec
et
al
patient
aeipf
surviv
month
suspect
aeipf
slightli
delay
onset
seven
patient
surviv
morawiec
et
al
anoth
studi
report
nine
patient
treat
ctx
discharg
median
surviv
period
month
simonblanc
et
al
novelli
et
al
report
monthsurviv
rate
surviv
year
novelli
et
al
studi
either
ctx
cyclosporinea
csa
administ
corticosteroid
report
monthsurviv
rate
corticosteroid
either
ctx
csa
except
studi
hozumi
et
al
hozumi
et
al
analyz
patient
aeipf
treat
corticosteroid
either
ctx
csa
monthsurviv
rate
also
evalu
efficaci
corticosteroid
monotherapi
corticosteroid
ctx
separ
use
propens
scorematch
method
compar
outcom
patient
treat
corticosteroid
ctx
patient
treat
corticosteroid
monotherapi
match
use
propens
score
differ
monthsurviv
rate
two
group
corticosteroid
ctx
group
vs
corticosteroid
control
group
major
studi
csa
control
studi
howev
retrospect
use
histor
control
group
shown
tabl
three
monthsurviv
csa
group
higher
match
corticosteroid
control
group
inas
et
al
homma
et
al
sakamoto
et
al
studi
kataoka
et
al
csa
control
group
rhtm
group
monthsurviv
lower
observ
rhtm
group
kataoka
et
al
tacrolimu
immunosuppress
use
mainli
prevent
reject
solid
organ
transplant
treatment
connect
tissu
diseas
tacrolimu
inhibit
cell
activ
helper
cell
cytokin
similar
csa
potent
also
prevent
immun
activ
inhibit
nuclear
factor
kb
nfkb
tgfbinduc
collagen
deposit
horita
et
al
compar
effect
tacrolimu
five
patient
aeipf
histor
control
group
patient
corticosteroid
monthsurviv
rate
tacrolimu
group
median
surviv
day
higher
control
group
day
surviv
patient
tacrolimu
group
reexacerb
least
month
initi
ae
wherea
four
nontacrolimu
group
patient
die
reexacerb
month
initi
ae
horita
et
al
recent
evid
shown
immun
inflamm
autoantibodi
may
involv
ipf
progress
aeipf
balestro
et
al
treatment
reduc
autoantibodi
might
benefit
subset
patient
ipf
kahloon
et
al
feghalibostwick
et
al
therefor
autoantibodi
reduct
therapi
includ
therapeut
plasma
exchang
tpe
corticosteroid
puls
rituximab
follow
intraven
immunoglobulin
studi
critic
ill
patient
aeipf
nine
patient
show
improv
pulmonari
ga
exchang
compar
one
among
patient
histor
control
group
donaho
et
al
monthsurviv
rate
trial
subject
surviv
ae
vs
among
histor
control
result
studi
addit
trial
ongo
list
clinicaltrialsgov
therapeut
plasma
exchang
rituximab
iv
ig
sever
acut
exacerb
ipf
admit
icu
exchangeipf
openrandom
control
phase
autoantibodi
reduct
acut
exacerb
idiopath
pulmonari
fibrosi
striveipf
due
implic
neutrophil
aeipf
efficaci
neutrophil
elastas
inhibitor
sivelestat
combin
corticosteroid
examin
mechan
ventil
patient
aeipf
four
patient
surviv
day
survivor
pao
fio
arteri
oxygen
tensionfract
inspir
oxygen
creactiv
protein
posit
endexpiratori
pressur
peep
level
improv
nakamura
et
al
pmxdhp
origin
develop
remov
endotoxin
gramneg
bacteria
base
potenti
column
absorb
endotoxin
plasma
proinflammatori
profibrot
proangiogen
cytokin
reactiv
oxygen
speci
activ
neutrophil
use
pmxdhp
column
studi
patient
acut
respiratori
distress
syndrom
ard
improv
oxygen
observ
therapi
cruz
et
al
open
label
pilot
trial
pmxdhp
six
patient
aeipf
demonstr
monthsurviv
rate
seo
et
al
sever
retrospect
cohort
studi
perform
report
month
surviv
rate
tabl
biggest
studi
abe
et
al
perform
pmxdhp
patient
interstiti
pneumonia
includ
aeipf
patient
type
interstiti
pneumonia
nonspecif
interstiti
pneumonia
nsip
organ
pneumonia
op
might
respond
high
dose
corticosteroid
patient
given
corticosteroid
therefor
respons
may
sole
due
pmxdhp
studi
monthsurviv
aeipf
abe
et
al
four
control
trial
use
pmxdhp
two
studi
perform
aeipf
patient
studi
report
better
surviv
pmxdhp
group
enomoto
trial
three
monthsurviv
rate
pmxdhp
group
similar
control
respect
yearsurviv
rate
significantli
better
pmxdhp
group
vs
enomoto
et
al
howev
data
interpret
caution
sever
patient
age
year
sever
comorbid
cardiovascular
instabl
exclud
pmxdhp
group
put
control
group
oshi
et
al
also
report
better
surviv
pmxdhp
group
report
month
surviv
rate
respect
contrast
control
group
two
studi
includ
variou
type
interstiti
pneumonia
furthermor
addit
corticosteroid
agent
ctx
csa
tacrolimu
sivelestat
anticoagul
administ
studi
period
furusawa
et
al
ichiyasu
et
al
itchyasu
report
among
patient
aeipf
differ
month
surviv
pmxdhp
control
group
howev
type
iip
includ
analysi
surviv
better
pmxdhp
group
ichiyasu
et
al
similarli
studi
furusawa
et
al
among
patient
aeipf
differ
overal
surviv
pmxdhp
control
group
furusawa
et
al
therefor
order
determin
effect
pmxdhp
aeipf
doubl
blind
random
control
studi
requir
thrombomodulin
thrombin
receptor
endotheli
cell
surfac
recombin
human
thrombomodulin
rhtm
form
revers
complex
thrombin
activ
plasma
protein
c
exhibit
antiinflammatori
anticoagul
antifibrinolyt
properti
collard
et
al
studi
plasma
biomark
profil
aeipf
found
mechan
ventil
log
chang
thrombomodulin
signific
predictor
surviv
aeipf
collard
et
al
due
hypercoagul
state
aeipf
tsushima
et
al
prospect
tri
rhtm
report
surviv
higher
patient
aeipf
compar
six
histor
control
vs
sever
retrospect
studi
use
histor
control
parallel
untreat
control
show
promis
result
monthsurviv
rate
around
better
observ
control
group
tabl
howev
small
studi
medic
like
nacetylcystein
nac
ctx
csa
anticoagul
even
pmxdhp
administ
studi
subject
trial
therefor
phase
placebo
control
random
trial
recent
perform
finish
recruit
macrolid
acceler
apoptosi
neutrophil
remov
cell
debri
macrophag
azithromycin
also
modul
effect
fate
well
lineag
adapt
immun
wuyt
et
al
azithromycin
inhibit
product
aberr
proinflammatori
cytokin
alveolar
macrophag
dosedepend
way
cai
et
al
suggest
potenti
role
treatment
ipf
azithromycin
evalu
retrospect
studi
surviv
aeipf
patient
significantli
better
compar
fluoroquinolonetr
histor
control
p
kawamura
et
al
use
japanes
diagnosi
procedur
combin
dpc
databas
oda
et
al
perform
retrospect
epidemiolog
prognost
analysi
patient
ipf
receiv
mechan
ventil
highdos
corticosteroid
without
ctx
cotrimoxazol
found
treatment
cotrimoxazol
macrolid
significantli
associ
better
prognosi
highdos
cyclophosphamid
significantli
associ
poor
prognosi
monthssurviv
rate
median
surviv
time
day
pirfenidon
nintedanib
shown
reduc
progress
ipf
may
use
aeipf
furuya
et
al
found
among
case
aeipf
treat
high
dose
corticosteroid
nac
ctxcsa
rhtm
monthsurviv
rate
significantli
better
patient
receiv
pirfenidon
patient
receiv
pirfenidon
vs
p
among
patient
receiv
rhtm
n
pirfenidon
make
signific
differ
outcom
vs
p
furuya
et
al
univari
analysi
nonus
rhtm
potenti
risk
factor
death
hazard
ratio
hr
p
patient
nonus
pirfenidon
potenti
risk
factor
death
hr
p
recent
vianello
et
al
report
improv
median
surviv
time
pirfenidon
group
day
compar
nine
retrospect
control
patient
day
p
vianello
et
al
howev
studi
mani
limit
includ
small
number
patient
older
age
lower
lung
function
histor
control
group
panther
trial
report
harm
effect
combin
use
corticosteroid
nac
azathioprin
therefor
nonsteroid
approach
immedi
cessat
immunosuppress
therapi
best
support
care
broadspectrum
antimicrobi
thorough
evalu
detect
revers
caus
deterior
tri
result
least
compar
surviv
rate
month
year
median
surviv
time
month
furthermor
histori
immunosuppress
therapi
includ
corticosteroid
ae
exert
less
favor
prognosi
papiri
et
al
review
proven
effect
drug
treatment
aeipf
agent
potenti
random
control
trial
ongo
present
support
care
mainstay
therapi
critic
ill
patient
includ
palliat
symptom
correct
hypoxemia
supplement
oxygen
current
ipf
guidelin
state
major
patient
respiratori
failur
due
ipf
receiv
mechan
ventil
may
reason
minor
weak
recommend
lowqual
evid
noninvas
ventil
niv
may
appropri
base
high
inhospit
mortal
observ
aeipf
mallick
fibrot
noncompli
lung
suscept
ventilatorinduc
lung
injuri
protect
ventil
ie
low
tidal
volum
strategi
niv
mollica
et
al
tomii
et
al
vianello
et
al
highflow
nasal
cannula
oxygen
koyauchi
et
al
faverio
et
al
may
reduc
risk
rush
et
al
analyz
data
nationwid
inpati
sampl
unit
state
found
invas
mechan
ventil
imv
higher
inhospit
mortal
rate
compar
niv
imv
vs
niv
p
among
patient
ipf
rush
et
al
japan
among
patient
receiv
imv
dayand
surviv
rate
respect
oda
et
al
lung
transplant
last
resort
recommend
intern
guidelin
highli
select
patient
aeipf
extracorpor
membran
oxygen
ecmo
may
use
bridg
transplant
may
minim
risk
ventil
induc
lung
injuri
trigger
fatal
deterior
underli
fibrot
process
moerer
quintel
recent
advanc
techniqu
enabl
ambulatori
ecmo
awak
spontan
breath
ecmo
bridg
lung
transplant
shown
encourag
result
garcia
et
al
hakim
et
al
ecmo
revers
origin
prognosi
appropri
consid
ecmo
lung
transplant
candid
trudzinski
et
al
even
ecmo
prognosi
patient
wors
lung
transplant
stabl
ipf
patient
therefor
recommend
elig
patient
ipf
need
transplant
evalu
earli
cours
diseas
episod
aeipf
previous
inhospit
mortal
aeipf
report
patient
mechan
ventil
inhospit
mortal
overal
mortal
among
case
report
mallick
howev
recent
studi
suggest
slightli
better
surviv
monthsurviv
rate
rang
month
rate
rang
surviv
hospit
discharg
kondoh
et
al
patient
treat
imv
niv
inhospit
surviv
rate
report
imv
niv
unit
state
rush
et
al
daysurviv
rate
monthsurviv
rate
japan
oda
et
al
median
surviv
patient
ipf
experi
ae
approxim
month
leuschner
behr
prevent
effect
medic
treatment
ae
avoid
trigger
factor
import
vaccin
influenza
viru
pneumococcu
shown
effect
prevent
respiratori
infect
import
trigger
factor
ae
vaccin
along
hand
wash
avoid
sick
contact
especi
winter
season
recommend
gerd
anoth
import
risk
factor
ae
use
pharmacolog
nonpharmacolog
therapi
reduc
ger
appropri
prevent
measur
howev
recent
studi
report
antacid
therapi
increas
risk
overal
pulmonari
infect
patient
advanc
ipf
ie
fvc
therefor
riskbenefit
ratio
care
evalu
individu
patient
larg
doubl
blind
rct
perform
avoid
airborn
irrit
pollut
strategi
minim
mechan
ventilatorinduc
lung
injuri
consid
patient
ipf
therapi
benefici
treatment
ipf
may
reduc
risk
aeipf
acut
exacerb
key
secondari
endpoint
three
placebocontrol
clinic
trial
nintedanib
phase
trial
nintedanib
treatment
ipf
tomorrow
demonstr
lower
incid
investigatedreport
aeipf
vs
per
year
risk
ratio
p
delay
time
first
investigatorreport
aeipf
subsequ
phase
trial
time
first
aeipf
significantli
delay
hazard
ratio
p
hazard
ratio
p
richeldi
et
al
howev
prespecifi
sensit
analysi
pool
data
demonstr
nintedanib
significantli
delay
time
first
adjud
aeipf
either
confirm
suspect
compar
placebo
hazard
ratio
p
separ
pool
analysi
three
trial
tomorrow
demonstr
reduct
central
adjud
confirm
suspect
aeipf
nintedanib
therapi
placebo
vs
nintedanib
p
collard
et
al
howev
result
need
interpret
caution
number
event
rel
small
signific
differ
mortal
observ
investig
report
ae
adjud
ae
adjud
nota
form
acut
respiratori
worsen
collard
et
al
time
first
adjud
aeipf
prespecifi
pool
analysi
time
first
investigatorreport
aeipf
separ
pool
analysi
three
trial
tomorrow
demonstr
delay
random
nintedanib
phase
trial
pirfenidon
perform
japan
termin
earli
statist
signific
reduct
ae
subject
receiv
pirfenidon
azuma
et
al
episod
aeipf
occur
exclus
placebo
group
subject
none
pirfenidon
group
month
p
howev
subsequ
trial
japan
replic
result
ae
occur
pirfenidon
control
group
subsequ
multin
phase
clinic
trial
pirfenidon
perform
western
countri
ascend
trial
includ
ae
endpoint
recent
ley
et
al
analyz
pool
data
three
rct
capac
ascend
found
pirfenidon
associ
lower
risk
respiratoryrel
hospit
compar
placebo
vs
hr
p
allcaus
hr
p
nonrespiratoryrel
hospit
hr
p
associ
treatment
ley
et
al
pirfenidon
also
suggest
reduc
risk
ae
postop
iwata
et
al
report
incid
postsurgeri
ae
patient
lung
cancer
ipf
lower
pirfenidon
pretreat
group
compar
nontreat
group
vs
iwata
et
al
also
perform
phase
clinic
trial
found
reduc
incid
ae
iwata
et
al
although
studi
sever
limit
includ
small
number
subject
singlearm
design
suggest
potenti
role
prevent
use
periop
pirfenidon
clear
whether
either
agent
withheld
continu
exacerb
event
richeldi
et
al
kuse
et
al
report
reduc
incid
ae
patient
treat
macrolid
addit
convent
drug
month
followup
period
compar
patient
given
macrolid
aefre
surviv
rate
macrolid
group
significantli
better
nonmacrolid
group
p
suggest
potenti
benefici
effect
macrolid
therapi
prevent
ae
kuse
et
al
first
consensu
statement
revis
statement
aeipf
better
defin
progress
knowledg
incid
risk
factor
trigger
factor
made
prognosi
favor
although
still
associ
highmort
rate
proven
effect
therapi
sever
new
innov
therapi
studi
suggest
potenti
benefit
treatment
aeipf
result
initi
sever
doubl
blind
random
clinic
trial
prophylact
measur
better
defin
emerg
data
suggest
efficaci
antifibrot
drug
prevent
aeipf
